Cargando…

Evaluating harm associated with anti-malarial drugs: a survey of methods used by clinical researchers to elicit, assess and record participant-reported adverse events and related data

BACKGROUND: Participant reports of medical histories, adverse events (AE) and non-study drugs are integral to evaluating harm in clinical research. However, interpreting or synthesizing results is complicated if studies use different methods for ascertaining and assessing these data. To explore how...

Descripción completa

Detalles Bibliográficos
Autores principales:	Allen, Elizabeth N, Chandler, Clare IR, Mandimika, Nyaradzo, Pace, Cheryl, Mehta, Ushma, Barnes, Karen I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Methodology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848530/ https://www.ncbi.nlm.nih.gov/pubmed/24041367 http://dx.doi.org/10.1186/1475-2875-12-325

Ejemplares similares

Working towards consensus on methods used to elicit participant-reported safety data in uncomplicated malaria clinical drug studies: a Delphi technique study
por: Mandimika, Nyaradzo, et al.
Publicado: (2017)

Eliciting harms data from trial participants: how perceptions of illness and treatment mediate recognition of relevant information to report
por: Allen, Elizabeth N, et al.
Publicado: (2011)

How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral interaction trials
por: Allen, Elizabeth N, et al.
Publicado: (2013)

Grading fluorescein angiograms in malarial retinopathy
por: MacCormick, Ian J. C., et al.
Publicado: (2015)

Automated and unsupervised detection of malarial parasites in microscopic images
por: Purwar, Yashasvi, et al.
Publicado: (2011)

Towards optimal design of anti-malarial pharmacokinetic studies
por: Simpson, Julie A, et al.
Publicado: (2009)

The recording of adverse events from psychological treatments in clinical trials: evidence from a review of NIHR-funded trials
por: Duggan, Conor, et al.
Publicado: (2014)

A framework for assessing the risk of resistance for anti-malarials in development
por: Ding, Xavier C, et al.
Publicado: (2012)

New molecular settings to support in vivo anti-malarial assays
por: Bahamontes-Rosa, Noemí, et al.
Publicado: (2016)

Improved negative selection protocol for Plasmodium berghei in the rodent malarial model
por: Orr, Rachael Y, et al.
Publicado: (2012)

The ACTwatch project: methods to describe anti-malarial markets in seven countries
por: Shewchuk, Tanya, et al.
Publicado: (2011)

Quantum dots: a new tool for anti-malarial drug assays
por: Ku, Min-Je, et al.
Publicado: (2011)

Dried blood spots as a source of anti-malarial antibodies for epidemiological studies
por: Corran, Patrick H, et al.
Publicado: (2008)

Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development
por: Zaloumis, Sophie, et al.
Publicado: (2012)

Assessing anti-malarial drug effects ex vivo using the haemozoin detection assay
por: Rebelo, Maria, et al.
Publicado: (2015)

Methods for implementing a medicine outlet survey: lessons from the anti-malarial market
por: O’Connell, Kathryn A, et al.
Publicado: (2013)

Application of the automated haematology analyzer XN-30 for discovery and development of anti-malarial drugs
por: Tougan, Takahiro, et al.
Publicado: (2019)

Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations
por: Khalil, Insaf F, et al.
Publicado: (2011)

A simple and inexpensive haemozoin-based colorimetric method to evaluate anti-malarial drug activity
por: Men, Tran Thanh, et al.
Publicado: (2012)

Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling
por: Hodel, Eva Maria, et al.
Publicado: (2014)

Development of a genetic tool for functional screening of anti-malarial bioactive extracts in metagenomic libraries
por: Mongui, Alvaro, et al.
Publicado: (2015)

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)—estimation of adverse event risks
por: Stegherr, Regina, et al.
Publicado: (2021)

Pill characterization data streams for reducing exposure to inadequately identified anti-malarial medication in developing countries
por: Pennefather, Peter, et al.
Publicado: (2010)

Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study
por: Ozawa, Sachiko, et al.
Publicado: (2019)

One-step concentration of malarial parasite-infected red blood cells and removal of contaminating white blood cells
por: Trang, Dai Thi Xuan, et al.
Publicado: (2004)

Multiple treatment comparisons in a series of anti-malarial trials with an ordinal primary outcome and repeated treatment evaluations
por: Youdom, Solange Whegang, et al.
Publicado: (2012)

A lactate dehydrogenase ELISA-based assay for the in vitro determination of Plasmodium berghei sensitivity to anti-malarial drugs
por: Orjuela-Sánchez, Pamela, et al.
Publicado: (2012)

COIL: a methodology for evaluating malarial complexity of infection using likelihood from single nucleotide polymorphism data
por: Galinsky, Kevin, et al.
Publicado: (2015)

Optimization of a multi-well colorimetric assay to determine haem species in Plasmodium falciparum in the presence of anti-malarials
por: Combrinck, Jill M., et al.
Publicado: (2015)

Characterization and optimization of the haemozoin-like crystal (HLC) assay to determine Hz inhibiting effects of anti-malarial compounds
por: Tempera, Carolina, et al.
Publicado: (2015)

Mosquitoes as a feasible sentinel group for anti-malarial resistance surveillance by Next Generation Sequencing of Plasmodium falciparum
por: Smith-Aguasca, Rebecca, et al.
Publicado: (2019)

Clinical utility of overviews on adverse events of pharmacological interventions
por: Sachse, Thilo, et al.
Publicado: (2023)

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial
por: James, Elizabeth C., et al.
Publicado: (2020)

Monitoring adverse social and medical events in public health trials: assessing predictors and interpretation against a proposed model of adverse event reporting
por: Moody, Gwenllian, et al.
Publicado: (2019)

Predictive modeling of anti-malarial molecules inhibiting apicoplast formation
por: Jamal, Salma, et al.
Publicado: (2013)

A new double-antibody sandwich ELISA targeting Plasmodium falciparum aldolase to evaluate anti-malarial drug sensitivity
por: Tritten, Lucienne, et al.
Publicado: (2009)

Identifying rapidly parasiticidal anti-malarial drugs using a simple and reliable in vitro parasite viability fast assay
por: Linares, María, et al.
Publicado: (2015)

An improved SYBR Green-1-based fluorescence method for the routine monitoring of Plasmodium falciparum resistance to anti-malarial drugs
por: Dery, Victor, et al.
Publicado: (2015)

A reliable and rapid method for molecular detection of malarial parasites using microwave irradiation and loop mediated isothermal amplification
por: Port, Julia R, et al.
Publicado: (2014)

Comparison of anti-malarial drug efficacy in the treatment of uncomplicated malaria in African children and adults using network meta-analysis
por: Whegang Youdom, Solange, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hl7716bbns65ijb3ttv3aslep1